ABUS

Arbutus BiopharmaB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.30

Analysis reference price unavailable

Analysis 2026-10-08 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$4.80

Analysis reference price unavailable

Analysis 2026-10-08 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$2.80

Analysis reference price unavailable

Analysis 2026-10-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-08

AI commentary

The October 1 company release resolves the prior baseline's largest open question: the tender's final price and share count are confirmed. The $4.29 October 7 anchor is below the $5.00 tender price, but the offer was prorated and no causal explanation for subsequent trading was verified. Current analyst revisions and dependable news, options, short-interest, employee and social measurements were unavailable; zero-valued fields indicate missing data, not neutral readings. Low coverage and uncertain post-buyback liquidity warrant monitoring rather than a strong bullish rating.

RankAlpha Sentiment Codex - 2026-10-08

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-31catalystPost-tender valuation resetMedium impact

Arbutus accepted 46 million shares for cancellation at $5.00 each, spending $230 million and retiring about 23% of shares outstanding before the offer. The offer was oversubscribed, so $5.00 is not a continuing exit price or price floor. Monitor how the reduced share count and cash balance are reflected in trading; the October 31 date is an assessment horizon, not a company-announced event. The earlier 8-K attached an August 21 press release, while the final terms are confirmed by the October 1 company release. [#8-K-2026-08-21] [#PR-EARNINGS-2026-10-01] Company final tender results

2026-11-30eventGenevant dividend and post-buyback liquidityHigh impact

After receiving $178.4 million from the noncontingent Moderna settlement payment, Arbutus said it anticipated a material Genevant dividend in Q3 2026. Receipt and amount remain unconfirmed in the checked evidence. Confirmation, alongside an updated cash balance after the $230 million tender, would clarify development runway. The date is a monitoring horizon, not announced guidance. [#PR-2026-08-12] Company Q2 release [#PR-EARNINGS-2026-10-01]

2027-06-30catalystImdusiran Phase 2b executionHigh impact

Arbutus reported FDA alignment on a proposed Phase 2b design for imdusiran in chronic hepatitis B and said it would incorporate FDA feedback into a final protocol. Protocol completion and trial initiation could clarify timing and R&D spending, but no confirmed start or readout date was identified. The date is an assessment horizon. [#PR-2026-08-12] Company Q2 release

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-08 • Updated nightlySource: Internal modelMethodology